Pharsight

Nascobal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940714 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Feb, 2024

(4 months from now)

US7404489 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Mar, 2024

(5 months from now)

US9415007 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Jul, 2024

(9 months from now)

US7879349 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(9 months from now)

US8003353 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(9 months from now)

US7229636 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(9 months from now)

Nascobal is owned by Endo Pharms Inc.

Nascobal contains Cyanocobalamin.

Nascobal has a total of 6 drug patents out of which 0 drug patents have expired.

Nascobal was authorised for market use on 31 January, 2005.

Nascobal is available in spray, metered;nasal dosage forms.

Nascobal can be used as nasal administration of cyanocobalamin, supplement for vitamin b12 deficiencies, cyanocobalamin administration through nasal infusion.

The generics of Nascobal are possible to be released after 01 August, 2024.

Drugs and Companies using CYANOCOBALAMIN ingredient

Market Authorisation Date: 31 January, 2005

Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of NASCOBAL before it's drug patent expiration?
More Information on Dosage

NASCOBAL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic